Experience the forefront of nuclear medicine at the world-leading EANM meeting in Barcelona, October 4-8. Drop by the Minerva booth 117 to learn more about our fully integrated CRO and CDMO facility specialized in targeted radionuclide therapy and molecular imaging. We are looking very much forward to meeting with key scientists and industry leaders to discuss and share insights on the latest developments in the field of nuclear medicine.

Presentations

Minerva is proud to have collaborated on three abstracts to be presented at EANM.

Programmable Medicine will present preclinical data on Hydroxyl dendrimers (HDs), novel nanomedicines known to selectively target activated macrophages, conjugated to different chelators and radiolabeled with 177Lu. The in vivo and ex vivo biodistribution profiles were evaluated, and treatment with doses of up to 14.9 MBq [177Lu]Lu-DOTA-HD appeared to halt tumor progression. In combination with an anti-PD-1 antibody, this treatment resulted in tumor regression. These data demonstrate the potential of selectively targeting and killing activated macrophages as a therapeutic approach in oncology, particularly for tumors resistant to checkpoint inhibitors. The full results will be presented Sunday, October 5, 08:00-09:30; Session 204, OP-025.

An abstract by Precirix highlights the potential of 4AH29, a FAP-targeting single-domain antibody. Labelled with 131I and 111In, 4AH29 demonstrates good tolerability and favorable biodistribution profiles in Göttingen minipigs. Next, the data obtained with [111In]In-DOTA-4AH29 was used as a surrogate for the 225Ac- and 177Lu-labelled variants. Dosimetry of 225Ac, 131I, and 177Lu-labelled 4AH29 indicates that repeated administrations within the clinically tested range have the potential to treat future patients without exceeding kidney toxicity limits. The work will be presented Tuesday, October 7, 09:45-11:15; Session 1305, OP-593.

In the e-Poster session EP-0007, Blue Wave Therapeutics will showcase the development of radiolabelled alginate nanoparticles for glioblastoma treatment. More specifically, the study shows that RGD-alginate specifically binds to glioblastoma cells expressing αvβ3 integrin and RGD-alginate nanoparticles stably chelate the alpha-emitting radionuclide 225Ac. The work will be presented at the e-Poster Area EP-01.

Connect with us at EANM

Want to delve deeper into our fully integrated CRO and CDMO facility specialized in targeted radionuclide therapy and molecular imaging or discuss potential collaborations? Click here to book a meeting with us via our online schedular. Alternatively, visit us at Booth 117 during the conference for face-to-face discussions.

More information